Global Rizatriptan Drug Market Size, Share and Trends Analysis Report, By Type (Tablets and Capsules) (, By Indication (Nausea, Vomiting, Migraine, Headache, and Other Pains)), By End User (Hospital, Clinic, and Others), Forecast (2022-2028)

The global rizatriptan drug market is anticipated to grow at a significant CAGR of 7.6% during the forecast period (2022-2028). The major factors accelerating the growth of the market include rising cases of migraine, and increasing awareness regarding migraine and its treatment among population. Rizatriptan drug is prescribed for the treatment of migraine episodes. This drug comes under a class of medications known as selective serotonin receptor agonists. The major function of this drug is to narrow blood vessels. These blood vessels are present in the brain and this drug works on blocking the pain signals which arise in the brain. Rizatriptan drug also detects natural substances which are responsible for inducing pain in the body. These substances are blocked by rizatriptan drugs. This drug can reduce the frequency of migraine attacks but cannot prevent migraine episodes. However, side effects of this drug are tightness in the chest and drowsiness, which will hamper the growth of the rizatriptan benzoate market during the forecast period.

 

The global rizatriptan drug market is segmented by disease and by end-user. Based on disease, the market is sub-segmented into migraine episodes and others. Based on end-user, the market is sub-segmented into hospitals, clinics, and others. Migraine is a type of headache that can last up to 72 hours. Extreme cases of migraine episodes can result in vomiting with nausea. This affects the patients concretely as they are not in their senses. Along with medications, patients are given information about balanced meals and a healthy lifestyle. Pharmacologic and non-pharmacologic therapies are available for the treatment of migraine. In case of reducing the frequency of migraine attacks, Prophylactic therapy is mostly advised to patients. In case of a severe migraine attack, patients are advised abortive therapy. Prescription of triptans in migraine comes under abortive migraine therapy. As per the World Health Organization, the prevalence rate of migraine episodes is 10% globally. Around the world, in a proportion of one million people, 3000 migraine attacks occur every day.

 

Clinical research and development are paving way for more effective and concrete drugs in the treatment of migraine. For instance, in Sep 2021, the Application for the drug AXS-07 has been accepted by the Food and Drug Administration of the United States. This drug would be used for the treatment of migraine episodes. This drug has meloxicam which is a COX-2 preferential nonsteroidal anti-inflammatory drug and rizatriptan as an active ingredient. The investigational therapy which is done in this regard has decreased cases of pain signal transmission. Rizatriptan is a 5-HT agonist which is used in this drug. Data through which this application has been accepted is based on double-blind phase 3 momentum and intercept that provide efficacy and safety of this drug.

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Indication
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Teva Pharmaceuticals Ltd., and Others

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Rizatriptan Drug Market Report By Segment

By Type

• Tablets
• Capsules

By Indication

• Nausea
• Vomiting
• Migraine
• Headache
• Others

By End-User

• Hospital
• Clinic
• Others

 

Global Rizatriptan Drug Market Report By Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa